Previous Close | 29.98 |
1-Year Change | -35.33% |
6-Months Change | -28.6% |
3-Months Change | -17.09% |
Moving Avg (50d) | 31.016 |
Moving Avg (200d) | 44.017 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.66B |
Beta (3-Years) | 0.97 |
Revenue Growth (ttm) | 162.1% |
Net Profit Margin (ttm) | -34.97% |
Return On Assets (ttm) | -27.73% |
EPS (ttm) | -541.69 |
PE Ratio (ttm) | -0.06 |
Dividend Yield | % |
Asset Description: | Apellis Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-10-28 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
29.38 | 28.481 | 27.881 | 26.982 | 25.483 | 23.984 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |